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Abstract 
Development and differentiation of the mammary gland is dependent on the 
appropriate temporal expression of both systemically acting hormones and locally 
produced growth factors. A large body of evidence suggests that molecular crosstalk 
between these hormonal and growth factor axes are crucial for appropriate cell and 
tissue function. Two of the most important trophic factors involved in this process are 
the oestrogen (E) and insulin-like growth factor (IGF) molecular axes. The reciprocal 
crosstalk that exists between these pathways occurs at transcriptional/post-
transcriptional and translational/post-translational levels  regulates the expression 
and activity of genes involved in this process .In a clinical context an important 
consequence of such crosstalk in the mammary gland is the role which it may play in 
the aetiology, maintenance and development of breast tumours.  Although oestradiol 
(E2) acting through oestrogen receptors Į and ȕ (ERĮ/ȕ) is important for normal 
mammary gland function it can also provide a mitogenic drive to ER+ breast 
tumours. Therefore over several years anti-oestrogen therapeutic regimens in the 
form of selective oestrogen receptor modulators (SERMs – e.g. tamoxifen), 
aromatase inhibitors (AI e.g. anastrozole) or selective oestrogen receptor down 
regulators (SERDs – e.g. fulvestrant) have been used in an adjuvant setting to 
control tumour growth.  Although initial response   is usually encouraging, large 
cohorts of patients eventually develop resistance to these treatments leading to 
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tumour recurrence and poor prognosis .Although there are potentially many routes 
by which breast cancer (BC) cells could escape anti-oestrogen based therapeutic 
strategies one of the most studied  is the putative growth factor mediated activation 
of ER(s). Such E-independent activation of ER could provide a route of escape from 
classical anti-oestrogen based therapeutic strategies.  Because of this growth factor 
modulation of ER activity has been an intensively studied route of molecular 
crosstalk in the mammary gland. The insulin-like growth factors (IGF-1 and -2) are 
amongst the most potent mitogens for mammary epithelial cells and there is 
accumulating evidence that they interact with the E2 axis to regulate mitogenesis, 
apoptosis, adhesion, migration and differentiation of mammary epithelial cells. Such 
interactions are also bi-directional and E2 has been shown to regulate the expression 
and activity of IGF axis genes with the general effect of sensitising breast epithelial 
cells to the actions of IGFs and insulin. In this short review we discuss the evidence 
for the involvement of crosstalk between the insulin-like growth factor (IGF) and 
oestrogen axes in the mammary gland and comment on the relevance of such 
studies in the aetiology and treatment of BC. 
Keywords: insulin-like growth factor; oestradiol; breast cancer; endocrine 
resistance 
 
1.1 Introduction 
In the mammary gland  IGF activity is regulated as part of a multi-component 
molecular axis comprising the growth factors themselves IGF-1 and IGF-2; the cell 
surface IGF-1 and IGF-2 receptors: IGF-IR and IGF-2R; and six well characterised 
soluble IGF binding proteins: IGFBP 1-6 [1, 2]. Ancillary members of the axis include 
IGFBP related proteins IGFBPrP-1 and 2 – sometimes called IGFBP-7 and -8 [3, 4], 
specific and non-specific IGFBP proteases [5]  and an acid labile subunit (ALS) 
protein which complexes with IGFBP-3 and IGFBP-5 in serum and interstitial fluids 
[6]. IGF-1 and -2 are small (~7.5kDa) polypeptides which show structural and 
functional homology to insulin [7] although unlike insulin IGFs are expressed by 
several tissues and cell types. The IGF-1R also shows a high degree of homology 
with the insulin receptor (IR) and hybrid IGF-1R/insulin receptor species have been 
reported for both the A and B isoforms of the insulin receptor ( IR-A / IR-B)  
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comprising an IGF-1R Įȕ dimer combined with an Įȕ dimer of  the IR-A or IR-B 
isoform. Although the physiological significance of hybrid receptor expression 
remains unknown they have been reported in BC cells [8]. The IGF-2R has no 
structural homology to either IGF-1R or IR and is a single chain transmembrane 
protein identical to the cation-independent mannose-6-phosphate receptor [9]. 
This partial structural homology amongst the ligands and receptors in the IGF and 
insulin  family leads to a degree of promiscuity in ligand binding and also results in 
some functional redundancy between IGF-1, IGF-2 and insulin polypeptides [10] . 
Binding of IGF-I to IGF-1R leads to recruitment of adaptor proteins belonging to the 
insulin receptor substrate (IRS) family of proteins to autophosphorylated regions 
within the cytosolic domain of IGF-1R with subsequent activation of downstream 
signalling molecules including Shc/Grb2, Ras/Raf-1, MAPK/Erk and PI3K/Akt. 
Ultimately such signalling pathways control various cellular functions including 
mitogenesis, apoptosis, adhesion, migration and differentiation [11].  
 IGF activity is modified by soluble high affinity IGFBPs which are present 
ubiquitously in biological fluids. IGFBPs can exert enhancing or inhibiting effects on 
IGF action [12, 13] or display IGF independent effects [14, 15]. IGFBPs are secreted 
by several cell types and show tissue specific expression profiles. They are 
expressed and secreted by BC cell lines and primary breast tissue cultures and the 
role of these proteins in the regulation of normal and abnormal breast epithelial cell 
function has been intensively studied.  IGFBPs are substrates for IGFBP proteases 
which act to release IGFs from IGFBPs allowing access of growth factors to cell 
surface receptors. BC cell lines and primary cultures also express and secrete such 
proteases [16, 17] and it is suggested that the activity of these enzymes may 
regulate access of growth factors to malignant breast epithelial cells [18]. It is clear 
therefore that the intuitive view of the sequestration and thus inhibition of IGF activity 
by IGFBPs is an over simplification of the biological reality in those tissues such as 
the breast where multiple components of the IGF axis are expressed. Therefore the 
potential role of the IGF axis in the functioning of normal mammary gland and 
possible role in BC is predicated on a comprehensive understanding of the 
expression and activity of the axis in normal and tumourigenic breast tissue. A 
diagrammatic representation of the principle genes and components of the IGF axis 
is outlined in Fig 1. 
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1.2 IGF axis expression and function in mammary gland   
 In vitro cell culture models (mainly BC lines) have been used extensively to examine 
IGF axis effects on various biological end points including cell mitogenesis, 
migration, adhesion, apoptosis and less commonly differentiation [1, 12, 14, 15]. 
Although the data generated is on occasion contradictory, in some instances findings 
reported in vitro have been confirmed in vivo by the use of conditional knock out or 
tissue specific over expression of IGF axis genes in the mammary gland. 
Initially the role of IGFs in the function of normal and malignant breast tissue was the 
subject of some controversy. This was mainly due to reports of low or absent IGF 
expression in cultures of mammary epithelial cell lines or primary breast epithelial 
cell cultures. Although early reports described the accumulation of IGF-1 in medium 
conditioned by BC lines [19, 20] this activity was subsequently shown to be 
associated with incomplete extraction of IGFBPs from media samples leading to an 
over estimation of IGF activity by radio-immunoassay procedures in use at that time 
[21, 22].  mRNA analysis confirmed very low levels of IGF-1 and -2 expression in BC 
epithelial cells [23] and although experiments with an inhibitory monoclonal antibody( 
Mab) specific for the IGF-1R suggested an autocrine role for secreted IGF-1 in BC 
epithelial cell proliferation [24] such experiments were often confounded by the use 
of inappropriate basal culture conditions used to examine the effects of added 
growth factors on cell division [25].  Further  experiments  led to the suggestion that 
in vivo in breast tissue IGFs are secreted mainly by stromal cells to act in a paracrine 
manner on closely associated epithelial cells [26, 27]. Consistent with this 
hypothesis, the expression of IGF-1R and IGF-2R in BC cell lines and primary 
mammary epithelial cell cultures is well established and following the initial 
demonstration of IGF-1  stimulation of thymidine incorporation in MCF-7 and T47-D 
BC lines  [28]  several groups have confirmed that BC cell lines and primary cultures  
are exquisitely sensitive to mitogenic stimulation by both IGF-1 and IGF -2 [25, 29-
32].  IGF-1 also displays well characterised anti-apoptotic effects in MCF-7 cells, a 
feature which may be associated with a permissive role for the growth factor in the 
establishment of tumour cells [33]. The use of antibodies which specifically block 
IGF-1R together with specific knockdown of IGF-1R expression suggest that the 
mitogenic action of both IGF-1 and -2 are  probably mediated by the IGF-1R [24, 31, 
34-39]. However IGF-2 may signal separate defined biological end points through its 
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own cognate receptor in BC cells and binding of both IGF-2 and insulin to cognate 
receptors in BC cells has been confirmed [40, 41].   
 IGFBP expression in mammary tissue and BC cells is well documented and it was 
suggested that IGFBP sequestration of growth factor inhibited IGF action in BC cells 
[42, 43]. Accordingly agents which increased pericellular IGFBP, including vitamin D 
analogues and anti-oestrogens (see below) attenuated the mitogenic activity of IGFs 
in BC cultures. However, a major confounding factor is the many observations which 
report an enhancing action of IGFBPs on IGF activity in BC cells [12-14]. Although 
the mechanisms of these enhancing effects are not fully elucidated amongst the 
theories postulated include the establishment of a low affinity “sink” formed by ECM 
bound IGFBP-IGF complexes (see Fig 1) or an increased half-life of IGFBP bound 
IGF compared with free IGF. It has also been suggested that IGFBPs may inhibit the 
IGF-1 induced desensitisation of IGF-1R and prolong the activity of growth factor [13] 
and  some reports also indicate that IGFBPs may have a direct IGF independent 
activity in breast tissues [44]. These findings introduce a further layer of complexity 
to studies which examine the activity of the IGF axis in BC cell physiology and are 
especially important for a full understanding of potential mechanisms involved in 
cross talk between IGF axis and other hormones/growth factors in normal mammary 
gland and BCs.  
 In BC cells the profile of IGFBP expression is cell line specific and correlates with 
oestrogen receptor (ER) status.  ER+ MCF-7 cells express IGFBP-2, -4 and -5 at 
moderate to high levels [45-47] while under basal conditions the expression of 
IGFBP-1, -3 and -6 is very low. This particular pattern of IGFBP secretion is by and 
large replicated in other ER+ BC cells [31, 48, 49] although there is some 
inconsistency in reports of IGFBP-3 expression in MCF-7 cells [50-53]. It is difficult to 
rationalise these inconsistencies although one explanation may be associated with 
the degree of cell confluence under which studies are conducted. IGFBP-3 
expression is reported to be up regulated in senescent cells [54-56] and it may be 
that in confluent cultures of MCF-7 cells this gene is expressed. At least one study 
demonstrating IGFBP-3 expression used confluent cultures of cells [51] and our 
studies which reported low IGFBP-3 levels used cultures which were 70-80% 
confluent (data not shown). Alternatively IGFBP-3 expression may vary with cell 
passage number.  IGFBP-3 expression was also increased by treatment with anti-
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oestrogens or retinoic acid derivatives. Although the significance of these studies 
remains open to interpretation the hypothesis has been advanced that increased 
IGFBP-3 expression mediated by such agents is mechanistically associated with 
their growth inhibitory properties and may have significance in vivo [51, 53, 57-60] 
.However the mechanism by which such effects  occur is not fully established and 
regulation of IGFBP-3 concentration was often evident at the post transcriptional 
level and in some instances was not associated with concomitant increases in 
IGFBP concentrations in conditioned medium [58, 59].  Such disjunction between 
gene expression and protein secretion may be due to proteolysis of IGFBPs and 
proteases which act on binding proteins  are expressed in BC cells [16, 17]. This 
further highlights some of the difficulties in interpretation of IGF axis effects on 
mammary epithelial cells and in the potential disruption of the axis which may occur 
in BC cells.  
1.3 IGF – E crosstalk: general considerations 
The observation that IGF and oestrogen axes interact within the mammary gland to 
regulate mammary cell physiology is well established and is an active research area.  
It is postulated that a greater understanding of such crosstalk mechanisms may shed 
light on potential involvement of the IGF axis on the escape of ER+ mammary 
tumours from anti-oestrogen therapies (see Abstract). Although the discussion which 
follows separates these directions of cross talk between the E and IGF axes it is 
important to appreciate that this is somewhat artificial and that cross talk between 
IGF and E2 signalling pathways is bi-directional. This was exemplified in early 
studies in uterine cell cultures demonstrating reciprocal phosphorylation of ERĮ and 
IGF-1R following treatment of cell cultures with IGF-1 or E2 respectively [61, 62]. The 
direction of E2 crosstalk to the IGF axis displays an extra level of complexity derived 
from the multi-component nature of the IGF axis and E2 affects the expression and 
activity many of these components (IGFs, IGFRs and IGFBPs). A review of the 
published data in this area highlights some inconsistencies usually related to the 
non-uniform use of standardised tissue culture methods. The most meaningful 
experiments have been conducted on cells usually maintained in the absence of 
Phenol Red (an oestrogenic stimulant) and under serum free or in the presence of 
dextran-charcoal stripped serum preparations. Ultimately examination of added 
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tropic factors against a completely E2 and serum free background gives the most 
reliable and robust data.  
Although crosstalk between IGF and E is important in mammary gland function it is 
also important to appreciate that IGF and E independently regulate an overlapping 
set of genes in mammary tissue and that this may have consequences for the 
development of BC treatments. An elegant microarray based study in MCF-7 cells 
demonstrated over 450 genes which were co-regulated by both IGF-1 and E2 [63]. 
Interestingly this pool was enriched in genes involved in aspects of DNA replication 
and metabolism. Similarly co-repressed genes included known or putative tumour 
suppressors. The clinical significance of these findings were underscored in an 
analysis of ERĮ +ve breast tumour samples where an “activated IGF-E2  signature” 
was associated with a shorter time to metastasis in these patients.  
The ultimate goal of cell line work is to eventually translate this information into the 
clinic. A good example of this is selective estrogen receptor down-regulator 
Fulvestrant (Faslodex), developed as a therapy from initial experiments showing that 
anti-estrogens regulated the growth of tamoxifen-stimulated MCF-7 cells [64]. In a 
similar vein the role of the IGF1R signaling pathway in clinical breast cancer is now 
beginning to be explored in trials. It is known that diabetic women who are treated 
with metformin have a lower risk of breast cancer and results from a retrospective 
cohort study showed that diabetic breast cancer patients receiving metformin had a 
better response rate with neoadjuvant chemotherapy than patients who received 
other forms of diabetic medication [65]. As a result, a trial is underway examining the 
effects of 5 years of adjuvant metformin versus placebo in pre- and postmenopausal 
women with either ER-positive or ER-negative breast cancer post-surgery and 
chemotherapy [66] One of the biological end points is the effect of metformin on 
plasma insulin levels. However data from the MA.17 trial was less promising showing 
no benefit and even some adverse effects of octreotide, one of the first IGF-1 
targeting agents available in the clinic, plus 5 years of tamoxifen on disease-free or 
overall survival [67] While it would appear there is still some way to go before the 
IGF-1 pathway can be effectively targeted in humans, cell line work can be a very 
effect vehicle to identify potential pathways and targets for therapeutic development. 
Further studies into the molecular details associated with co-regulation of mammary 
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gland gene expression and the potential significance for BC treatment is fully 
warranted. 
 
1.4 IGF axis effects on ER function 
Since early studies using subcutaneous implants of des (1-3) IGF-1 (an IGF-1 
analogue with reduced affinity for IGFBPs but native affinity for IGF-1R) 
demonstrated an enhanced effect of E2 on growth factor stimulated terminal end bud 
formation and alveolar development in mammary gland [68] there has been a great 
deal of interest in the mechanistic aspects of this hormone-growth factor interaction. 
As discussed above, the main route described for IGF cross talk to oestrogen 
signalling mechanisms is through the regulation of ERĮ activity by IGF-1. In vitro this 
has usually been reported as an alteration in phosphorylation status of ERĮ following 
IGF-1 treatment. Although ERĮ is subject to extensive post translational 
modifications [69]  the growth factor mediated phosphorylation of serine residues 
S118 and S167 in the AF-1 domain of human ERĮ have been the most intensively 
studied and there is some evidence that this route of E2 independent activation of 
ERĮ may be partly involved in the development and maintenance of tumourigenesis 
in breast tissue  [1, 70, 71].  In this fashion, IGF-1 (and other GFs) may allow the 
escape of ERĮ+ breast tumours from anti-oestrogen therapeutic regimens [72, 73]. It 
is important to note however that this hypothesis is challenged by clinical data which 
relate the phosphorylation status of ERĮ with such parameters as disease free 
survival (DFS) in various cohorts (see below). 
  IGF-1 stimulates serine phosphorylation of ERĮ at S118 in an Akt dependent 
manner [74] and the receptor is subsequently translocated to the cell membrane   
with resulting activation of the MAPK cascade [61, 75]. It is known that IGF-1 acts via 
MAPK to phosphorylate ERĮ at S118 [76] and this suggest that both Akt and MAPK 
signalling pathways converge at S118. The significance of these findings is not fully 
understood but different pathways of IGF-1 signalling may show cell specificity in 
activation profiles. IGF-1 also acts  via PI3K/Akt to phosphorylate at S167 within the 
AF-1 domain of ERĮ [77] and  phosphorylated ERĮ subsequently associates with 
many components of the IGF signalling pathway including IRS proteins [78],  Shc 
[79] PI3K [80] and IGF-1R itself [81]. In this manner ERĮ may regulate the 
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expression, stability and intracellular localisation of these signalling intermediates 
[75, 82, 83]. Recent studies suggest that mTor/S6K1 lies down stream of Akt in the 
pathway of S167 phosphorylation although somewhat unusually this study did not 
demonstrate simultaneous S118 phosphorylation of ERĮ after IGF-1 treatment of 
MCF-7 cells [84]. The ERĮ protein is in fact a somewhat promiscuous substrate and 
is phosphorylated at S118 by several different kinases [85-87]. Whether there is a 
cell or tissue type specificity associated with individual kinase activity on ERĮ 
remains largely unknown but further elucidation of specificities associated with 
kinase modification of ERĮ activity is of obvious physiological significance. 
There may also be important developmental and temporal aspects associated with 
IGF-E axis interaction in breast tissue.  An elegant study using transgenic mice 
expressing IGF-1 in the mammary gland from the bovine keratin 5 (BK5) promoter 
demonstrated developmentally regulated control of IGF-E crosstalk.  In pre-pubertal 
animals IGF-1 signalling was dominated by the PI3K/Akt pathway and the presence 
of an IRS-1/ERĮ complex was clearly identified. In post pubertal animals with lower 
levels of ERĮ expression no such complex was observed and the main route for 
signalling proceeded via the Ras/Raf MAPK pathway [88]. Such differences in 
signalling patterns may differentially affect tumourigenesis during different 
developmental stages and indicate a potential role for ERĮ in routing IGF signalling 
pathways. IGF-1 may phosphorylate ERĮ at sites other than S118/S167. Studies 
with S305A mutant ERĮ suggest S305 as important IGF-1/IRS-1/Akt mediated 
phosphorylation site [89] and this modification may regulate acetylation at the nearby 
K303 residue regulating sensitivity of ERĮ to E2 activation [89, 90]. Two excellent 
reviews on the characterisation and physiological significance of phosphorylated 
ERĮ isoforms are available [91, 92] and Fig 2 shows some of the IGF dependent 
pathways of ERĮ serine phosphorylation. 
There is limited data on the interaction of other IGF axis genes and ER function. A  
recent report indicates that silencing IGFBP-2 expression leads to a loss of ERĮ 
expression in MCF-7 and T47D cell lines and that expression can be up regulated in 
wild type (wt) cells by the addition of exogenous IGFBP-2 [93].and the authors 
provide evidence for an anti-apoptotic role of IGFBP-2 by a mechanism which is 
dependent on ERĮ expression. Conversely, IGFBP-4 and -5 have been reported to 
inhibit E2 induced ERĮ activity in MCF-7 cells possibly via a PI3-K/Akt dependent 
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pathway resulting in an  inhibition of E2 stimulated cell growth [94]. However in this 
study E2 treatment did not stimulate IGF-1R phosphorylation nor did IGF-1 addition 
stimulate ERĮ phosphorylation. Both of these observations run counter to the current 
weight of evidence. Also in this study neither IGFBP-4 nor -5 were detectable by 
Western blot of non-transfected MCF-7 cell conditioned medium despite the fact that 
the expression and secretion of these proteins by ER+ BC cell lines has been widely 
reported in the literature [95]. Despite these caveats the area of IGFBP crosstalk with 
ERs is very new and no doubt will provide much interesting data in the near future. 
It is interesting to position studies of IGF-ER crosstalk within a clinical setting. 
Phosphorylation of ERĮ is generally viewed as an activating post translational 
modification (PTM) [96, 97] and is postulated as a route of escape of ER+ BC cells 
from SERM therapeutic strategies – see above. However, some evidence from 
immunohistochemical (IHC) screening of archived BC tissues using a well 
characterised anti-pS118-ERĮ antibody  suggests that phosphorylation of ERĮ at 
S118 is associated with longer relapse free survival  and longer time to progression  
in tamoxifen treated cohorts [98, 99]. While this does not necessarily negate a role 
for IGF-1 stimulated phosphorylation at S118 as an activating PTM, at the moment it 
is difficult to reconcile these observations although other factors such as precise 
patterns of PTMs of ERĮ, temporal aspects related to PTMs or intracellular location 
of ERs may prove to be significant. 
Much less data is available on the IGF-1 mediated regulation of ERȕ. No effect of 
IGF-1 on ERȕ expression in the MDA-MB-231 cell line was reported [100] although 
pro- IGF-2 may stimulate translocation of ERȕ to intracellular organelles in the 
Hs578T and basal-like BC line CRL-2335 [101]. This latter observation may have 
some clinical relevance as high localised levels of mature IGF-2 have been reported 
in early stage BC [27]. In prostate cancer cells  ERȕ (and ERĮ) can associate with 
Src and the p85 subunit of PI3K in an E2 dependent fashion and up regulate IGF-1R 
expression [102]. Knockdown of IGF-1R in MCF-7 cells using siRNA increases ERȕ 
expression and the subsequently altered ERȕ: ERĮ ratio may increase apoptosis via 
activation of tumour suppressor p53 [103]. The phosphorylation of the ERȕ isoform 
has also been described [104] although whether such modification is regulated by 
IGF axis activity is currently unknown. However the mouse ERȕ is phosphorylated at 
S106 and S124 via the MAPK pathway [105] and as the former residue is conserved 
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as S118 in human ERĮ it raises the possibility that ERȕ may be subject to similar 
IGF-1 mediated PTMs as ERĮ. In addition ERȕ has at least 5 alternatively spliced 
variants (ERȕ1-5) which are expressed in a cell and tissue specific manner and 
which may display differential functions [106]. A novel route for growth factor 
modulation of ERȕ function may be through the regulation of the differential 
expression of receptor isoforms. To date there is little information in this area 
although it is a subject of ongoing research in our laboratories. 
The G protein coupled oestrogen receptor (GPER30) is the most recently described 
ER [107]. This cell membrane associated protein is believed to be partly responsible 
for the rapid non-genomic effects of E2 – reviewed in [108].  Very little data is 
available on crosstalk between GPER and the IGF axis although a recent report 
indicates that IGF-1 up regulates GPER expression in MCF-7 cells in a PKCį/ERK 
dependent fashion [109]. Interestingly this effect was dependent on ERĮ activity 
suggesting a close relationship between these two ERs. In addition IGF-1R 
associates with the G protein linked chemokine receptor CXCR4 in the MDA-MB-231 
cells leading to an IGF-1 mediated dissociation of GĮ2 and Gȕ subunits from the 
complex with associated stimulation of chemotaxis [110]. Whether such a 
mechanism(s) exists for the GPER receptor is currently unknown. 
1.5 ER crosstalk to IGF axis 
As indicated above the evidence for IGF -1 and/or IGF-2 expression in BC cell lines 
and in primary tumour epithelial cells is not convincing however mammary stromal 
cells express IGF-1 and -2 and this population may provide a source of local growth 
factor [111].With this in mind an intriguing  hypothesis suggests that E2  increases 
vascular permeability via a VEGF dependent mechanism and thus allows access of 
circulating growth factors (including IGFs) to cell surface receptors [112]. The extent 
to which this mechanism may operate in the mammary gland requires further 
investigation. Irrespective of whether such a mechanism operates there is 
compelling data that E2 can increase the expression of IGF-1R on the surface of BC 
epithelial cells [113-116]. Up regulation of IGF-1R expression may occur through 
interaction between liganded ERĮ and the trans-acting zinc finger transcription factor 
Sp1 at the IGF-1R promoter [117]. More recent evidence indicates that in the PC3 
prostate cancer cell line E2 also up regulates IGF-1R expression via a c-Src/ERK1/2 
mediated activation of the cyclic AMP response element binding (CREB) protein 
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which subsequently acts as a trans activating factor within a defined enhancer region 
in the IGF-1R promoter [118] see Fig 3. The resulting increase in IGF-1R density in 
breast epithelial cell membranes may account for the sensitisation of cells to the 
mitogenic effects of paracrine IGF-1 following E2  exposure [119].  Some findings 
also suggest that E2 decreases IGF-2R expression in both ERĮ+ and ERĮ- BC cell 
lines thus routing the mitogenic action of IGF-2 via the IGF-1R and possibly the A 
isoform of the insulin receptor (IR-A) [120, 121]. 
 As well as influencing IGF-1R expression, E2 treatment stimulates phosphorylation 
of IGF-1R. In MCF-7 cells E2 stimulated tyrosine phosphorylation of IGF-1R is 
dependent on ERĮ expression and Shc activity [75] and these latter two proteins 
physically associate through interaction between the AF-1 domain of ERĮ and the 
phosphotyrosine binding SH2 domain of Shc [79]. E2 induced activation of IGF-1R 
leads to downstream MAPK signalling [122]. An important upstream element in the 
activation of MAPK by this route may be the matrix metalloproteinase -2/9 (MMP-2/9) 
mediated release of heparin bound EGF (HB-EGF) and subsequent activation of 
EGF receptor signalling [123] and in this sense E2 mediated IGF-1R activation can 
be viewed as lying up stream of EGF-R.  Such mechanisms may provide alternative 
routes for ER+ tumour escape from SERM based chemotherapy. The effects of E2 
on  IGF-1R function discussed above are commonly referred to as  “ non-genomic”  
ERĮ activity [124] and are associated with a localisation of ERĮ out with the nucleus 
- typically at the plasma membrane where it is in juxtaposition with growth factor 
receptors and associated signalling complexes. Changes in signalling associated 
with ERs complexed with such membrane and cytosolic signalling complexes are 
temporally acute and are differentiated from the more chronic alterations in gene 
expression associated with the classical nuclear action of ERs as direct trans acting 
transcription factors at oestrogen response elements (EREs) or as accessory 
transcription factors at other non-ERE cis acting promoters. However changes in 
plasma membrane and cytosolic signalling events often ultimately lead to changes in 
gene expression and as such the commonly used term “non-genomic” may be 
somewhat misleading. 
 E2 also influences the expression and activity of other IGF signalling components. 
Perhaps one of the most important of these is the insulin receptor substrate (IRS) 
family of signalling molecules [117]. These adaptor proteins directly bind to activated 
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IGF-1R in a phosphotyrosine (pY)  dependent manner and following their own 
receptor catalysed tyrosine phosphorylation provide docking sites for other  proteins 
involved in IGF-1 signalling including the p85 subunit of PI3K, Grb2 and Jak1. As 
such the role of IRS family proteins in BC is a subject of intense study – reviewed in 
[125]. In essence E2 acts as a positive factor in IRS function. Thus, as for IGF-1R, E2 
can enhance IRS-1 expression via activation of transcription factor Sp1 [126]. In 
addition, ERĮ is reported to bind and stabilise IRS-1 protein [78] leading to increased 
signalling through the IGF-1 pathway [127]. The sum effect of ERĮ action on IRS-1 is 
to reinforce the stimulatory action on IGF-1R function and provide a mitogenic drive 
toward cell division. In this context, it is important to appreciate that the ultimate 
molecular effect of IGF-E2 cross talk is to enhance the transition of cells through the 
cell cycle process and involves the regulation of G1-S phase cell cycle progression 
through the regulation of key regulators such as cyclinD1 or c-myc [73]. Limitations 
of space prevent a detailed discussion of this area but the E2-IGF control of cell cycle 
regulation is an important area of research with respect to BC progression and the 
interplay between the axis in the control of this process is an area of active study 
[101, 128].  
There is much less evidence for a direct route of functional cross talk between E2 
and IGFBPs. Most studies have been concerned with profiling IGFBP expression in 
ER+ and ER- cells and with investigation of the effects of E2 on IGFBP expression. – 
(see above) One study reported that E2 stimulated secretion IGFBP-2, -4 and -5 in 
MCF-7 cells [129]. Although the contribution of such studies to any causality in E2 – 
IGF axis crosstalk has not been determined such findings suggest that E2 stimulation 
of IGFBP expression does not inhibit mitogenic activity through any autocrine 
mechanisms as ER+ remain mitogenically sensitive to added E2 under these 
conditions. Such arguments also indicate prima facia that under basal conditions of 
cell growth the mitogenic effects of E2 are unlikely to be mediated by the very low 
levels of IGFs reported in most BC cell culture models in turn suggesting that 
autocrine regulation of BC cell growth by IGF-1 is not a tenable hypothesis (see 
above). Although IGFBPs may act in an IGF independent manner to stimulate BC 
cell mitogenesis [1] whether this is a potential mechanism of action for the mitogenic 
action of E2 requires rigorous experimental verification and in general terms the role 
of IGFBPs in BC cell physiology requires further investigation and clarification. 
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1.6 Clinical implications  
The development of resistance to SERM treatment in ER+ breast tumours presents 
a major therapeutic challenge in the treatment and management of this cancer. The 
molecular phenotypes associated with such escape from SERM control are the 
subject of intense study through such techniques as gene array and extensive 
proteomic analyses. The design of studies aimed at investigating this phenomenon 
have been predicated on the recruitment of alternative mitogenic signalling pathways 
by cancer cells resulting in continued tumour cell growth and metastasis. It is in this 
context that studies of signalling cross talk discussed in this paper may have some 
clinical relevance. In vitro, BC cell lines can acquire tamoxifen resistance through 
growth in the presence of drug. Although caution must be exercised in the 
interpretation of findings using such cells, especially with regard to their clinical 
relevance, this model is useful for the examination of signalling pathways which may 
be activated in tamoxifen resistant breast tumours. The MCF-7 cell line is most 
commonly used in this research and there is a small literature which describes 
perturbations in IGF axis expression and function in such cells following the 
acquisition of tamoxifen resistance. For example, increased IGF-1R expression in 
tamoxifen resistant cells may enhance E2 independent growth of the cells and an 
early study in wt and TamR cells suggested that this may indeed occur [130]. 
However subsequent literature in this area is contradictory with reports describing 
both the up regulation [131-133] and down regulation [134-136] of IGF-1R 
expression in TamR cells and the significance of altered IGF-1R activity in the 
development of TamR remains under investigation. Nonetheless, there is evidence 
that in TamR cells which have also developed resistance to the EGF-R inhibitor AG 
1478 subsequent cell growth is largely dependent on activation of the IGF-1R [137]. 
This may provide a mechanism of escape of BC cells from both anti-oestrogen and 
anti-EGF-R (Herceptin) based therapy.  
Considerations such as these have led to the investigation of anti-IGF directed 
therapeutic strategies aimed at regulation BC progression. Essentially these 
strategies involve three different classes of compound – 1. Anti-IGF-1R monoclonal 
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antibodies (Mabs); 2- less commonly Mabs directed towards IGF-1/IGF-2; 3 – 
tyrosine kinase inhibitors (TKIs) designed to inhibit of IGF-1R signalling activity. Such 
reagents have been used to target many solid and blood based tumours although we 
restrict ourselves to a discussion of the use of these strategies in BC. In the adjuvant 
setting, anti-IGF directed strategies may be used as mono-therapy or more 
commonly in association with anti-oestrogen directed therapy (SERM, SERD or AI). 
Although such protocols are currently the subject of numerous clinical trials it is fair 
to say that results to date have not been encouraging with the latest report of lack of 
efficacy of the humanised anti-IGF-1R Ganitumab in combination with either 
exemestane (AI) or fulvestrant (SERD) in increasing progression free survival 
compared to placebo with anti-oestrogen therapy [138] one of several negative 
studies which has encouraged the pharmaceutical industry to withdraw from this 
area. However, some consideration of possible reasons for the failure of such 
approaches may lead to the development of improved strategies [139]. A recent 
study indicated that the acquisition of tamoxifen resistance in MCF-7 cells was 
associated with decreased IGF-1R expression and subsequent impaired activation of 
Akt activation in response to IGF-1. The subsequent lack of effect of anti-IGF1R 
antibodies demonstrated in vitro may provide a rationale for the general lack of 
clinical utility demonstrated by these reagents in clinical trials and indicate that 
alternative strategies may be required for treatment of TamR tumours[140].  For 
those reagents developed as Mabs against the IGF-1R concern has been expressed 
that increased activation of the insulin receptor could arise due to increased level of 
serum insulin. Such an effect may occur secondarily to increases in pituitary growth 
hormone (GH) secretion due to incomplete feedback by IGF-1 subsequent to IGF-1R 
blockade. Typically anti-IGF-1R Mabs are not effective at the IR and thus under 
these circumstances increased signalling may occur through this IR. Prophylactic 
treatment with metformin has been investigated in attempt to deal with the 
hyperinsulinemia which is evident in these circumstances [135]. Alternatively, 
elevated IGF-1 levels subsequent to GH elevation may activate IGF-1R if anti-IGF-
1R directed Mabs are not able to completely inhibit ligand binding. In addition to this 
a heterogeneous array of IR/IGF-1R is often displayed on the surface of tumour cells 
which comprise alternatively spliced forms of the IR and IGF-1R present either as 
holo-receptors or hybrid receptors comprising the Įȕ subunits of  IR in association 
with the Įȕ subunits of IGF-1R. Such variation in receptor presentation may call for a 
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more sophisticated approach to the development of Mabs with appropriate blocking 
activities at individual receptors. Such observations also argue for the careful 
analysis of appropriate clinical specimens prior to decisions on potential therapies 
and informs in the general area of patient selection based on appropriate biomarker 
expression. Due to some of these findings an alternative route of developing small 
molecule inhibitors of receptor tyrosine kinase activity (TKIs) has been pursued [18] 
and several of these compounds are currently under investigation in clinical trials. 
Indeed a combination of Mab/TKI directed therapy is clearly feasible and may have 
advantages over treatment with either agent alone. More recently the development 
of specific kinase inhibitors has allowed the combination of anti-IGF directed 
therapies with inhibitors of the mTOR serine/threonine kinase in treatment of solid 
tumours and have generated some encouraging preliminary data [141, 142]. 
Due to some of the difficulties associated with manipulation of IGF receptor and 
ligand activity outlined above there has been a level of ongoing interest in the third 
main component of the IGF axis -the IGFBPs- and their possible role in the 
development of BC. .Some early studies reported altered IGFBP profiles on the 
acquisition of tamoxifen resistance by the MCF-7 and ZR-75-1 cell lines. However 
the species of BP reported in this study were not identified immunologically but only 
by molecular weight on ligand blot [143]. Subsequently the same group identified 
IGFBP-2 as down regulated in TamR MCF-7 cell lines [144] although 
dexamethasone – a known regulator of IGFBP expression in mammary epithelial cell 
lines [145] - was present in these cultures. We have shown that IGFBP-5 is down 
regulated at both mRNA and protein levels in TamR MCF-7 cells (unpublished 
observations). This may have biological significance as this binding protein has been 
shown to inhibit growth of BC cells [15] and IGFBP-5 treatment of BC tumour cells in 
a xenograft mouse model has been shown to restore tamoxifen sensitivity [146]. 
Similarly, the mechanism of action of the SERD fulvestrant may be associated with 
increased expression of IGFBP-5 in BCs [115]. Fulvestrant treatment of MCF-7 cells 
enhances ERĮ association with IGF-1R in a Src dependent fashion and is 
associated with ERĮ translocation to the plasma membrane, phosphorylation of IGF-
1R and MAPK activation.[124]. These findings are unexpected for a drug whose 
principle use is in the inhibition of BC cell mitogenesis by enhancing ERĮ 
degradation and the findings of this study are important enough to require 
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independent confirmation. As for studies with wt BC cells any causality between 
alterations IGFBP expression and acquisition of TamR remains to be established. 
Although we and others have clearly demonstrated IGFBP-5 down regulation in 
these circumstances our preliminary observations suggest that IGFBP-2 is up 
regulated in TamR cells. Given the functional redundancy that exists in the IGFBP 
family with respect to high affinity binding of IGFs this argues that any effects of 
locally altered IGFBP concentrations in a TamR environment most likely would occur 
in an IGF independent manner. However, there are studies which report distinct, 
differential and IGF-independent effects of IGFBPs in BC cells. For example IGFBP-
3 was reported to enhance ceramide or paclitaxel induced apoptosis in the human 
Hs578T BC cell line whereas IGFBP-4 and -5 inhibited ceramide induced apoptosis 
[147, 148]. In an extension of these studies the direct IGF-independent effects of 
IGFBP-3 and -5 on cell survival, attachment and apoptosis were found to be 
regulated by the presence of fibronectin in the ECM [12]. As perturbation in ECM 
composition and structure are a common feature in many tumours, including breast, 
such observations may have important clinical consequences. A further refinement 
of the action of IGFBP-3 was reported from the same group who demonstrated cell 
line specific effects of IGFBP-3 on cell survival which was also dependent on the 
liganded status of the ȕ1 integrin receptor [149]. Clearly there are many factors 
which influence potential activities of IGFBP in the pericellular environment of breast 
tissue including the local concentrations of different IGFBP species. Further 
extensive experimentation is required to outline the detail of IGFBP action in 
mammary gland and possible role(s) in BC and how such activity may be related to 
the development of resistance to SERM or AI treatment.    
1.7 Concluding remarks 
Although this review has focussed on crosstalk between the E and IGF axes we 
would highlight to the reader that E also interacts with other growth factor axes. 
Understanding the biology behind steroid-growth factor crosstalk has recently been 
emphasised as a 'knowledge gap' in a gap analysis conducted by a panel of breast 
cancer experts http://breast-cancer-research.com/content/15/5/R92. In the context of 
the mammary gland and BC perhaps the most significant of these is the crosstalk 
that exists between the ERĮ and members of the EGF family [150, 151]. As for IGF-1 
molecular crosstalk between EGF receptors and ERĮ is bi-directional and such 
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mechanisms may be associated with promotion of tumour cell growth. This area has 
been expertly reviewed [152]. In conclusion the interaction of E and IGF axes in the 
mammary gland is important not only for normal tissue function but may also be 
involved in breast tumour aetiology and progression. A further understanding of the 
mechanisms involved in this crosstalk will mostly likely impact on the future 
treatment of BCs which develop resistance to anti-oestrogen therapy. 
 
Figure Legends 
Fig 1 
 The IGF axis comprises six soluble high affinity IGF binding proteins (IGFBP1-6 – 
yellow) together with the cell surface IGF-1 receptor (IGF-1R - blue) and IGF-2 
receptor (IGF-2R - green). The insulin receptor (IR - red) and hybrid IR/IGF-1R are 
also able to bind IGFs although with lower affinity than cognate receptors. Similarly 
insulin and IGF-2 are able to bind to IGF-1R but with lower affinity than IGF-1 itself. 
Most IGFBPs can associate with various extra-cellular matrix (ECM) structures - 
shown is IGFBP-5- and can be hydrolysed are by various IGFBP proteases. Both of 
these features are used to regulate the access of pericellular IGFs to cell surface 
receptors. Recent evidence also suggests that some IGFBPs (shown is IGFBP-3) 
display IGF-independent effects by association with specific IGFBP receptors. In 
serum and other biological fluids IGFBP-3 and -5 can associate with an acid labile 
subunit (ALS). 
Fig 2 
Dual regulation of IGF-1 mediated phosphorylation of ERĮ. S118 in the AF-1 domain 
of ERĮ is phosphorylated by both PI3K and MAPK pathways. S167 and S305 are 
phosphorylated by PI3K mediated S6K1 activation. ERĮ is phosphorylated at several 
other S, T and Y residues by a range of cellular kinases (see text for further details). 
Fig 3 
E2 acting via ERĮ regulates IGF1IR expression via Src/Erk1/2 mediated activation of 
CREB at a distal enhancer region within the IGF-1R gene.  Gene expression is also 
stimulated by an E2/ERĮ dependent activation of Sp1 at a more proximal promoter 
site within the 5’ flanking region of the IGF-1R gene. For further details see text. 
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